Market Cap : 403.13 M | Enterprise Value : 467.41 M | PE Ratio : At Loss | PB Ratio : |
---|
NAS:HLVX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:HLVX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, HilleVax's enterprise value is $467.41 Mil. HilleVax does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2021. Therefore, GuruFocus does not calculate HilleVax's EV-to-EBITDA at this moment.
The historical rank and industry rank for HilleVax's EV-to-EBITDA or its related term are showing as below:
HLVX's EV-to-EBITDA is ranked worse thanEV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2022-08-14), HilleVax's stock price is $12.06. HilleVax does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021. Therefore, GuruFocus does not calculate HilleVax's PE Ratio at this moment.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for HilleVax's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HilleVax Semi-Annual Data | ||
Dec20 | Dec21 | |
EV-to-EBITDA | - | - |
For the Biotechnology subindustry, HilleVax's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, HilleVax's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where HilleVax's EV-to-EBITDA falls into.
HilleVax's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 467.405 | / | ||
= |
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
HilleVax's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 12.06 | / | ||
= |
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of HilleVax's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Fhmls X, L.l.c. | 10 percent owner | 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101 |
Dubin Gary | director | C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109 |
Borkowski Astrid | officer: Chief Medical Officer | C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109 |
Sepulveda Jaime | director | C/O HILLEVAX INC. 75 STATE STREET 100 - #9995 BOSTON MA 02109 |
Takeda Vaccines, Inc. | 10 percent owner | 75 SIDNEY STREET CAMBRIDGE MA 02139 |
Chu Shelley | director | ONE WINTHROP SQUARE SUITE 400 BOSTON MA 02110 |
Silbermann Susan Michele | director | C/O LIANBIO 103 CARNEGIE CENTER DRIVE, SUITE 215 PRINCETON NJ 08540 |
Fhmls X, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101 |
Frazier Life Sciences X, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101 |
Gerberding Julie L. | director | 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 |
Kohli Aditya | director, officer: Chief Operating Officer | C/O PHATHOM PHARMACEUTICALS, INC. 2150 E. LAKE COOK ROAD, SUITE 800 BUFFALO GROVE IL 60089 |
Socks David A | officer: CFO & Chief Business Officer | C/O CADENCE PHARMACEUTICALS, INC. 12481 HIGH BLUFF DRIVE, SUITE 200 SAN DIEGO CA 92130 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668 |
Hershberg Robert | director, officer: President and CEO | 3005 FIRST AVENUE SEATTLE WA 98121 |
Topper James N | 10 percent owner | 550 HAMILTON AVENUE, SUITE 100 PALO ALTO CA 94301 |
From GuruFocus
Other Sources
By tipranks.com 2022-05-25